Have a feature idea you'd love to see implemented?
Let us know!
GLUE Monte Rosa Therapeutics Inc
Price (delayed)
$4.87
Market cap
$298.89M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.23
Enterprise value
$229.53M
Highlights
The equity rose by 47% since the previous quarter and by 5% year-on-year
Monte Rosa Therapeutics's EPS has increased by 13% YoY and by 11% from the previous quarter
The quick ratio has declined by 39% year-on-year but it is up by 36% since the previous quarter
The net income has contracted by 4.1% YoY but it has grown by 3.6% from the previous quarter
Key stats
What are the main financial stats of GLUE
Market
Valuations
Earnings
Shares outstanding
61.37M
Market cap
$298.89M
Enterprise value
$229.53M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.09
Price to sales (P/S)
60.24
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
39.86
Revenue
$5.76M
EBIT
-$129.93M
EBITDA
-$122.29M
Free cash flow
-$67.76M
Per share
Balance sheet
Liquidity
EPS
-$2.23
Free cash flow per share
-$0.95
Book value per share
$4.45
Revenue per share
$0.08
TBVPS
$4.83
Total assets
$344.11M
Total liabilities
$119.44M
Debt
$44.36M
Equity
$224.67M
Working capital
$235.55M
Debt to equity
0.2
Current ratio
6.56
Quick ratio
6.54
Net debt/EBITDA
0.57
Margins
Efficiency
Dividend
EBITDA margin
-2,123.5%
Gross margin
100%
Net margin
-2,264.5%
Operating margin
-2,420.9%
Return on assets
-44.7%
Return on equity
-70.4%
Return on invested capital
-66.1%
Return on capital employed
-43.1%
Return on sales
-2,256.1%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
GLUE stock price
How has the Monte Rosa Therapeutics stock price performed over time
Intraday
0%
1 week
-11.29%
1 month
-14.41%
1 year
88.76%
YTD
-13.81%
QTD
-8.11%
Financial performance
How have Monte Rosa Therapeutics's revenue and profit performed over time
Revenue
$5.76M
Gross profit
$5.76M
Operating income
-$139.42M
Net income
-$130.41M
Gross margin
100%
Net margin
-2,264.5%
The net margin has surged by 82% since the previous quarter
The operating margin has surged by 82% since the previous quarter
The operating income has declined by 5% year-on-year but it has increased by 3.2% since the previous quarter
The net income has contracted by 4.1% YoY but it has grown by 3.6% from the previous quarter
Growth
What is Monte Rosa Therapeutics's growth rate over time
Valuation
What is Monte Rosa Therapeutics stock price valuation
P/E
N/A
P/B
1.09
P/S
60.24
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
39.86
Monte Rosa Therapeutics's EPS has increased by 13% YoY and by 11% from the previous quarter
The equity rose by 47% since the previous quarter and by 5% year-on-year
GLUE's P/B is 27% below its last 4 quarters average of 1.5
Efficiency
How efficient is Monte Rosa Therapeutics business performance
Monte Rosa Therapeutics's ROS has soared by 82% from the previous quarter
The ROIC has contracted by 48% YoY
GLUE's ROE is down by 43% year-on-year but it is up by 5% since the previous quarter
Monte Rosa Therapeutics's ROA has decreased by 15% YoY but it has increased by 9% from the previous quarter
Dividends
What is GLUE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for GLUE.
Financial health
How did Monte Rosa Therapeutics financials performed over time
GLUE's total assets is 188% greater than its total liabilities
The total liabilities has surged by 84% year-on-year and by 4.6% since the previous quarter
The company's current ratio fell by 40% YoY but it rose by 36% QoQ
The debt is 80% smaller than the equity
The equity rose by 47% since the previous quarter and by 5% year-on-year
The debt to equity has contracted by 33% from the previous quarter and by 9% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.